Oral Delivery of Large Molecules
Oral Delivery of Large Molecules
Home
About Us
Company Profile
Strategy
Management Team
Board of Directors
Technology
Oral Drug Delivery
Parathyroid Hormone
Supportive Publications
Pipeline
Progress Summary
Hypoparathyroidism
Osteoporosis
Bone Healing
News and Events
News
Events
Investors
Contact Us
Oral Delivery of Large Molecules
Sitemap
General
Investors
About Us
Strategy
Company Profile
tables
Hypoparathyroidism - Success in Phase IIa Clinical Trials
Technology
Hypoparathyroidism Market
Supportive Publications
Oral Drug Delivery
Key People
The Team
Adam Gridley-CEO
Dr. Phillip Schwartz President of R&D and Executive Vice President
Dr. Hillel Galitzer – COO
Dr. Roger Garceau - Chief Development Advisor
Dr. Arthur Santora - CMO
Dana Yaacov-Garbeli, CPA, - Interim Chief Financial Officer.
The Board
Mr. Gerald Lieberman - Chairman of the Board
Dr. Roger Garceau
Miranda J. Toledano
Mr. Zeev Bronfeld
Mr. Yonatan Malca
Dr. Phillip Schwartz
Faith L. Charles
Mr. Gerald M. Ostrov
Adam Gridley
Clinical Trials
News and Events
Events
ASMBR 2018
ASMBR 2017
ASMBR 2016
ASBMR 2012
ASBMR 2013
ASBMR 2014
ASBMR 2015
News
Osteoporosis - Animal Trials
Osteoporosis - Phase 1 Clinical Trials
Osteoporosis - Bioavalabilty
Osteoporosis - Cmax
Osteoporosis - Scale Up Trial
Hypoparathyroidism - Clinical Trials
Osteoporosis - Succesful Completion of Phase I
Osteoporosis – IRB Approval for Scale Up Trial
Osteoporosis – Results Support Hypoparathyroidism Application
Hypoparathyroidism - Orphan Drug Application
Hypoparathyroidism - Orphan Drug Approval
Hypoparathyroidism - Phase II
New Director – Gerald M. Lieberman
Hypoparathyroidism - Phase II Results
New Director – Luke M. Beshar
New Director – Roger L. Garceau
Hypoparathyroidism - Orphan Drug Approval (EMA)
Pipeline
Progress Summary
Hypoparathyroidism
Overview
Market
Current Status
Osteoporosis
Overview
Market
Current Status
Bone Healing
Overview
Market
Current Status
Main Menu
Home
About Us
Company Profile
Strategy
Management Team
Board of Directors
Technology
Oral Drug Delivery
Parathyroid Hormone
Supportive Publications
Pipeline
Progress Summary
Hypoparathyroidism
Osteoporosis
Bone Healing
News and Events
News
Events
Investors
Contact Us